Last reviewed · How we verify

MgSO4 plus Ropivacaine — Competitive Intelligence Brief

MgSO4 plus Ropivacaine (MgSO4 plus Ropivacaine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic adjuvant combination. Area: Anesthesiology.

marketed Local anesthetic adjuvant combination Voltage-gated sodium channels (ropivacaine); NMDA receptors and calcium channels (magnesium sulfate) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

MgSO4 plus Ropivacaine (MgSO4 plus Ropivacaine) — Hospital Universiti Sains Malaysia. Magnesium sulfate enhances the local anesthetic effect of ropivacaine by potentiating neural blockade and reducing pain transmission.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MgSO4 plus Ropivacaine TARGET MgSO4 plus Ropivacaine Hospital Universiti Sains Malaysia marketed Local anesthetic adjuvant combination Voltage-gated sodium channels (ropivacaine); NMDA receptors and calcium channels (magnesium sulfate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic adjuvant combination class)

  1. Hospital Universiti Sains Malaysia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MgSO4 plus Ropivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/mgso4-plus-ropivacaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: